Darsana Capital Partners LP Has Lowered Position in Alibaba Group Hldg LTD (BABA) by $77.40 Million; Armistice Capital Has Increased Vanda Pharmaceuticals (VNDA) Stake by $17.19 Million as Valuation Rose

April 17, 2018 - By Vivian Park

Armistice Capital Llc increased its stake in Vanda Pharmaceuticals Inc (VNDA) by 74.8% based on its latest 2017Q4 regulatory filing with the SEC. Armistice Capital Llc bought 1.15 million shares as the company’s stock rose 9.54% while stock markets declined. The institutional investor held 2.68 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $40.71 million, up from 1.53M at the end of the previous reported quarter. Armistice Capital Llc who had been investing in Vanda Pharmaceuticals Inc for a number of months, seems to be bullish on the $775.65 million market cap company. The stock increased 1.18% or $0.1774 during the last trading session, reaching $15.2274. About 226,569 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 15.63% since April 17, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.

Darsana Capital Partners Lp decreased its stake in Alibaba Group Hldg Ltd (BABA) by 90% based on its latest 2017Q4 regulatory filing with the SEC. Darsana Capital Partners Lp sold 450,000 shares as the company’s stock rose 3.18% while stock markets declined. The institutional investor held 50,000 shares of the business services company at the end of 2017Q4, valued at $8.62 million, down from 500,000 at the end of the previous reported quarter. Darsana Capital Partners Lp who had been investing in Alibaba Group Hldg Ltd for a number of months, seems to be less bullish one the $460.61B market cap company. The stock increased 2.61% or $4.56 during the last trading session, reaching $179.26. About 10.57 million shares traded. Alibaba Group Holding Limited (NYSE:BABA) has risen 68.29% since April 17, 2017 and is uptrending. It has outperformed by 56.74% the S&P500.

Among 38 analysts covering Alibaba (NYSE:BABA), 36 have Buy rating, 1 Sell and 1 Hold. Therefore 95% are positive. Alibaba had 171 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Alibaba Group Holding Limited (NYSE:BABA) earned “Buy” rating by SunTrust on Friday, August 12. On Tuesday, June 28 the stock rating was maintained by Morgan Stanley with “Overweight”. Oppenheimer maintained the shares of BABA in report on Monday, June 26 with “Buy” rating. Suntrust Robinson maintained Alibaba Group Holding Limited (NYSE:BABA) rating on Friday, August 12. Suntrust Robinson has “Buy” rating and $110 target. As per Tuesday, August 22, the company rating was maintained by Oppenheimer. The company was maintained on Friday, August 12 by Deutsche Bank. Deutsche Bank maintained it with “Buy” rating and $91 target in Thursday, March 24 report. Bank of America maintained the stock with “Buy” rating in Thursday, August 17 report. The firm has “Buy” rating by KeyBanc Capital Markets given on Thursday, October 19. Oppenheimer maintained Alibaba Group Holding Limited (NYSE:BABA) rating on Wednesday, October 28. Oppenheimer has “Outperform” rating and $90 target.

Darsana Capital Partners Lp, which manages about $989.03 million and $2.72 billion US Long portfolio, upped its stake in New York Times Co (NYSE:NYT) by 6.52 million shares to 14.52M shares, valued at $268.70 million in 2017Q4, according to the filing. It also increased its holding in Autodesk Inc (NASDAQ:ADSK) by 175,000 shares in the quarter, for a total of 1.85 million shares, and has risen its stake in Gray Television Inc (NYSE:GTN).

Analysts await Alibaba Group Holding Limited (NYSE:BABA) to report earnings on May, 4 before the open. They expect $0.71 EPS, up 82.05% or $0.32 from last year’s $0.39 per share. BABA’s profit will be $1.82B for 63.12 P/E if the $0.71 EPS becomes a reality. After $1.34 actual EPS reported by Alibaba Group Holding Limited for the previous quarter, Wall Street now forecasts -47.01% negative EPS growth.

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 24 analyst reports since September 2, 2015 according to SRatingsIntel. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Wednesday, February 28 by Seaport Global. The firm has “Buy” rating by Brean Capital given on Wednesday, October 21. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The company was initiated on Tuesday, June 27 by Piper Jaffray. The rating was maintained by Oppenheimer with “Buy” on Monday, March 5. The rating was maintained by Oppenheimer with “Outperform” on Monday, October 30. Jefferies reinitiated the shares of VNDA in report on Thursday, October 6 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Tuesday, February 13. The firm has “Buy” rating by Jefferies given on Monday, September 4. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, September 2.

Since January 2, 2018, it had 0 buys, and 8 sales for $4.89 million activity. Shares for $157,565 were sold by Gulino Richard L. on Tuesday, January 2. Shares for $1.14M were sold by Polymeropoulos Mihael Hristos. Shares for $159,712 were sold by Kelly James Patrick on Wednesday, February 28.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>